Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 609-333-1 | CAS number: 37143-54-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: other routes
Administrative data
- Endpoint:
- acute toxicity: other routes
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study meets generally accepted scientific principles. However, route of administration (i.p.) is not a recommended one.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 970
- Report date:
- 1970
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD Guideline 401
- Deviations:
- yes
- Remarks:
- the substance was injected into the peritoneal cavity
- Principles of method if other than guideline:
- BASF-TEST: The substance was injected into the peritoneal cavity. Young adult laboratory mice were purchased from breeder. Usually the source and strain of animals were not documented. Several groups of 5 mice per sex and dose were treated simultaneously with preparations of the test substance in suitable vehicle. The concentrations of these preparations were used to achieve comparable volumes per kg body weight. Group-wise documentation of clinical signs was performed over the 14 day study period. Body weight was determined before the start of the study only, as it was needed for determination of dose.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Reference substance 001
- Details on test material:
- - Name of test material (as cited in study report): Methoxyisopropylamin
- Physical state: liquid
Constituent 1
Test animals
- Species:
- mouse
- Strain:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Mean body weight at study initiation:
50 mg/kg bw dose group: males: 34 g / females: 28 g
100 mg/kg bw dose group: males: 37 g / females: 29 g
200 mg/kg bw dose group: males: 35 g / females: 30 g
400 mg/kg bw dose group: males: 32 g / females: 29 g
800 mg/kg bw dose group: males: 30 g / females: 30 g
1600 mg/kg bw dose group: males: 33 g / females: 28 g
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- other: traganth
- Details on exposure:
- DOSAGE PREPARATION:
- Stock solutions prepared:
1% for the 50 mm³/kg bw dose group,
1% for the 100 mm³/kg bw dose group,
2% for the 200 mm³/kg bw dose group,
4% for the 400 mm³/kg bw dose group,
8% for the 800 mm³/kg bw dose group,
20% for the 1600 mm³/kg bw dose group
- Dose volume applied:
5 ml/kg bw of the 1% stock solution for the 50 mm³/kg bw dose group;
10 ml/kg bw of the 1% stock solution for the 100 mm³/kg bw dose group;
10 ml/kg bw of the 2% stock solution for the 200 mm³/kg bw dose group;
10 ml/kg bw of the 4% stock solution for the 400 mm³/kg bw dose group;
10 ml/kg bw of the 8% stock solution for the 800 mm³/kg bw dose group;
8 ml/kg bw of the 20% stock solution for the 1600 mm³/kg bw dose group. - Doses:
- 50; 100; 200; 400; 800; 1600 mm³/kg bw.
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days;
- The animals were observed for mortality and clinical signs of toxicity;
- Frequency of observations: Several times on the application day, thereafter once each working day;
- Body weights were only recorded at the beginning of the study;
- Necropsy of survivors and animals which died performed: yes
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- ca. 200 other: mm³/kg
- Remarks on result:
- other: recalculation of LD50 to mg/kg bw not possible, due to missing information on density of the suspension applied.
- Clinical signs:
- 1600 mm³/kg bw.: Immediately after injection accelerated respiration, cavernous flanks and piloerection. Total exitus within 5 hours after application.
400-800 mm³/kg bw.: Immediately after application accelerated respiration, staggering and aggressiveness. Pain indicated by vocal response. Approx. 1.5 hours following injections in the 800 mm³/kg bw dose group lateral position, apathy, irregular intermittent respiration, cavern ous flanks, piloerection. Total exitus after 3.5 hours following application. Squatting posture and piloerection of the animals of the 400 mm³/kg bw. dose group which died on day 4 after application.
50-200 mm³/kg bw.: Immediately after application accelerated respiration, cavernous flanks, piloerection. The days following the application, the survi ving animals showed squattering posture, inactivity, irregular intermittent respiration, piloerection and apathy. After day 12 and 13, no abnormalities detected. - Body weight:
- Body weights were not recorded during and at the end of the observation period.
- Gross pathology:
- 50, 100 and 200 mm³/kg bw. dose group: some animals showed adhesions in the liver.
Decay was noted in some cases of the animals that died.
Any other information on results incl. tables
Dosis / kg cmm |
Conc. % |
Number animals |
died within |
||||
1 h |
24 h |
48 h |
7 d |
14 d |
|||
1600 |
20 |
5 m |
1 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 w |
0 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
||
800 |
8 |
5 m |
1 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 w |
0 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
||
400 |
4 |
5 m |
0 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 / 5 |
5 w |
0 / 5 |
4 / 5 |
4 / 5 |
5 / 5 |
5 / 5 |
||
200 |
2 |
5 m |
0 / 5 |
1 / 5 |
1 / 5 |
2 / 5 |
2 / 5 |
5 w |
0 / 5 |
1 / 5 |
1 / 5 |
2 / 5 |
2 / 5 |
||
100 |
1 |
5 m |
0 / 5 |
0 / 5 |
0 / 5 |
1 / 5 |
1 / 5 |
5 w |
0 / 5 |
0 / 5 |
0 / 5 |
0 / 5 |
0 / 5 |
||
50 |
1 |
5 m |
0 / 5 |
0 / 5 |
0 / 5 |
0 / 5 |
0 / 5 |
5 w |
0 / 5 |
0 / 5 |
0 / 5 |
0 / 5 |
0 / 5 |
||
Mortality of mice after oral application of methoxyisopropylamine. |
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.